You just read:

Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy

News provided by

Audentes Therapeutics, Inc.

May 16, 2018, 11:30 ET